Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial
Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial
复制标题
DOI：
10.1007/s10549-005-5199-2
复制
发表时间：
2005-10-01
影响因子：
3.8
通讯作者：
Holli, K
中科院分区：
文献类型：
--
作者：
Kokko, R;Hakama, M;Holli, K
我们在一项随机试验中研究了 472 名无远处转移的乳腺癌患者在四种不同方案的初级治疗后的随访费用。平均随访时间为 4.2 年。这四个时间表的不同之处在于随访频率（每三个月或每六个月一次）和诊断检查的强度（常规或临床检查）。就诊频率和诊断检查的强度对患者的无病生存率或总生存率没有任何影响。然而，四个随访计划的随访总成本有所不同，每个患者的随访费用在 1050 到 2269 Sigma 之间变化，每次检测到的复发费用在 4166 到 9149 Sigma 之间变化。与每六个月一次的门诊和无症状原发性乳腺癌患者随访中的常规检查相比，每三个月一次的门诊就诊并不能改善患者的无病生存率或总生存率，反而使随访成本增加了 2.2 倍。
We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic examinations (routine or on clinical grounds). Neither the frequency of visits nor the intensity of diagnostic examinations had any effect on disease-free or overall survival of patients. The total costs of follow-up, however, were different in the four follow-up schedules and varied between arms per patient from 1050 to 2269 Sigma and per detected recurrence from 4166 to 9149 Sigma. Outpatient visits every third month compared to every sixth month and routine examinations in the follow-up of asymptomatic primary breast cancer patients do not improve patient disease-free or overall survival, but increase the costs of follow-up 2.2 times.